Home / Business and Economy / Biotech's $100B Cancer Play: Illumina Soars
Biotech's $100B Cancer Play: Illumina Soars
1 Aug
Summary
- Illumina forecasts strong 2026 revenue and earnings growth.
- Clinical sequencing demand and NovaSeq X placements boosted results.
- Oncology, especially MRD, drives significant clinical adoption.
Illumina has raised its 2026 revenue and earnings projections following a strong second quarter that surpassed internal expectations. The biotech firm reported a 9.5% year-over-year revenue increase to $1.16 billion, with non-GAAP diluted earnings per share rising 10% to $1.31. Management highlighted this as the fastest revenue growth since the CEO joined.
The company's performance was significantly driven by clinical markets, which constitute about 65% of sequencing consumables revenue. Sequencing consumables saw a 5% increase year over year, largely due to expanded use of the NovaSeq X instrument. Specifically, clinical sequencing consumables revenue grew 15% excluding China, with over 20% growth in the U.S. and Canada.
Oncology remains the leading clinical application, with minimal residual disease (MRD) applications starting to contribute momentum. Therapy selection continues to be the primary revenue-generating application within clinical oncology, indicating a robust demand for Illumina's diagnostic technologies in cancer care.
